247 related articles for article (PubMed ID: 29674440)
21. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
Epperla N; Hamadani M; Cashen AF; Ahn KW; Oak E; Kanate AS; Calzada O; Cohen JB; Farmer L; Ghosh N; Tallarico M; Nabhan C; Costa LJ; Kenkre VP; Hari PN; Fenske TS
Hematol Oncol; 2017 Dec; 35(4):528-535. PubMed ID: 28066928
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
23. Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.
Phillips TJ; Bond D; Takiar R; Kump K; Kandarpa M; Boonstra P; Mayer TL; Nachar V; Wilcox RA; Carty SA; Karimi YH; Nikolovska-Coleska Z; Kaminski MS; Herrera AF; Maddocks K; Popplewell L; Danilov AV
Blood Adv; 2023 Aug; 7(16):4518-4527. PubMed ID: 37013954
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.
Zinzani PL; Rigacci L; Cox MC; Devizzi L; Fabbri A; Zaccaria A; Zaja F; Di Rocco A; Rossi G; Storti S; Fattori PP; Argnani L; Tura S; Vitolo U
Leuk Lymphoma; 2015 Jun; 56(6):1671-6. PubMed ID: 25241999
[TBL] [Abstract][Full Text] [Related]
25. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Ruan J; Martin P; Shah B; Schuster SJ; Smith SM; Furman RR; Christos P; Rodriguez A; Svoboda J; Lewis J; Katz O; Coleman M; Leonard JP
N Engl J Med; 2015 Nov; 373(19):1835-44. PubMed ID: 26535512
[TBL] [Abstract][Full Text] [Related]
26. Mantle cell lymphoma: the promise of new treatment options.
Goy A; Kahl B
Crit Rev Oncol Hematol; 2011 Oct; 80(1):69-86. PubMed ID: 21168343
[TBL] [Abstract][Full Text] [Related]
27. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Vose JM; Habermann TM; Czuczman MS; Zinzani PL; Reeder CB; Tuscano JM; Lossos IS; Li J; Pietronigro D; Witzig TE
Br J Haematol; 2013 Sep; 162(5):639-47. PubMed ID: 23834234
[TBL] [Abstract][Full Text] [Related]
28. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.
Dreyling M; Aurer I; Cortelazzo S; Hermine O; Hess G; Jerkeman M; Le Gouill S; Ribrag V; Trněný M; Visco C; Walewski J; Zaja F; Zinzani PL
Leuk Lymphoma; 2018 Aug; 59(8):1814-1828. PubMed ID: 29172868
[TBL] [Abstract][Full Text] [Related]
29. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
30. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers.
Zaja F; De Luca S; Vitolo U; Orsucci L; Levis A; Salvi F; Rusconi C; Ravelli E; Tucci A; Bottelli C; Balzarotti M; Brusamolino E; Bonfichi M; Pileri SA; Sabattini E; Volpetti S; Monagheddu C; Vacca A; Ria R; Fanin R
Haematologica; 2012 Mar; 97(3):416-22. PubMed ID: 22058200
[TBL] [Abstract][Full Text] [Related]
31. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
[TBL] [Abstract][Full Text] [Related]
32. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
33. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
[TBL] [Abstract][Full Text] [Related]
35. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.
Chong EA; Ahmadi T; Aqui NA; Svoboda J; Nasta SD; Mato AR; Walsh KM; Schuster SJ
Clin Cancer Res; 2015 Apr; 21(8):1835-42. PubMed ID: 25632047
[TBL] [Abstract][Full Text] [Related]
36. [Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
Vorobyev VI; Gemdzhian EG; Fedorova LV; Mikhailova NB; Ilyasov RK; Kaleikina LP; Trubyakova OS; Kaplanov KD; Melnichenko EV; Martynova EV; Yakovleva EP; Li OY; Tarasenko EV; Chumakova EP; Bulieva NB; Nesterova ES; Margolin OV; Zherebtsova VA; Butaev LS; Ptushkin VV
Ter Arkh; 2021 Jul; 93(7):770-777. PubMed ID: 36286727
[TBL] [Abstract][Full Text] [Related]
37. Novel agents in mantle cell lymphoma.
Tucker D; Rule S
Expert Rev Anticancer Ther; 2017 Jun; 17(6):491-506. PubMed ID: 28480764
[TBL] [Abstract][Full Text] [Related]
38. SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
Romancik JT; Gerber DG; Zhuang T; Cohen JB
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):557-565. PubMed ID: 35123927
[TBL] [Abstract][Full Text] [Related]
39. Treatment options for mantle cell lymphoma.
Smolewski P; Witkowska M; Robak T
Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
[TBL] [Abstract][Full Text] [Related]
40. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
